GOI has slapped a fine of Rs 230 crore against Johnson & Johnson

▴ National Anti-Profiteering Authority
he National Anti-Profiteering Authority (NAA) has slapped a fine of Rs 230 crore against Johnson & Johnson (J&J) for not passing on the benefits of goods and services tax (GST) rate cut to its customers.

The National Anti-Profiteering Authority (NAA) has slapped a fine of Rs 230 crore against Johnson & Johnson (J&J) for not passing on the benefits of goods and services tax (GST) rate cut to its customers.

“The methodology adopted by the respondent (J&J) while computing the benefit of tax reduction was illogical, unreasonable, arbitrary, and incorrect, and hence cannot be accepted,” the authority said in its order.

The NAA said that it was "absolutely clear that the respondent has not commensurately reduced prices but has, in fact, increased them by adding tax costs and losses from November 15, 2017, on the base prices that he was already charging."

It added that, therefore, it was clear that the company did not have any intention of passing on the benefit of tax cut to customers, according to a CNBC-TV18 report.

Tags : #nationalantiprofiteeringauthority #johnsonjohnson #medicircle

About the Author


Team Medicircle

Related Stories

12 Nov

Sanofi completes acquisition of Kadmon

Latest pharma news updates

View
20 Sep

Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics

Latest pharma news update

View
05 Aug

Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics

Corporate Pharma news upedat

View
17 Jul

LabGenius announces research collaboration with Ablynx, a Sanofi Company

Latest pharma update : Research and Collaboration

View
16 Jul

Sanofi extends collaboration with Genedata for Pharmaceutical Development & Manufacturing Science

Latest FDA approvals update

View
14 Jul

Sanofi streamlines Consumer Healthcare portfolio in Latin America with divestiture of eight brands to Hypera Pharma

As discussed during our Capital Markets Day in February, simplifying the CHC product portfolio is an important part of our strategy to focus our resources and efforts where we can bring the most value, especially to consumers.

View
09 Jul

Sanofi, GSK get approval for Phase 3 COVID-19 vaccine trial in India

In a two-stage approach, the study will initially investigate the efficacy of a vaccine formulation targeting the original virus strain (D.614), while a second stage will evaluate a second formulation targeting the Beta variant (B.1.351)

View
28 Apr

Moderna announces agreement with Sanofi for manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Moderna and Sanofi collaborate for covid vaccine manufacturing

View
18 Mar

ProBioGen licenses GlymaxX Technology to Sanofi

GlymaxX enables a boost of antibody-dependent cell-mediated cytotoxicity (ADCC)

View
15 Feb

Sanofi's mRNA vaccine would not be available this year ; CEO

It could be of use at a later stage all the more if the fight against variants was to continue, said the CEO

View

-Advertisements-




Trending Now

Maternal and Infant Health in Focus as India Observes World Health Day 2025April 05, 2025
Under 15 Children Under Threat: The TB Comeback No One Saw Coming April 04, 2025
MGM Healthcare Performs World's First Modified Multi-Visceral Transplant for Rare Intestinal DisorderApril 04, 2025
World Health Day 2025: St. George’s University’s Role in Preparing Doctors to Tackle Global Health ChallengesApril 04, 2025
Strength Doesn’t Retire: The Science Behind Ageless PowerApril 04, 2025
Beyond the Baby Bump: Can Delayed Pregnancy Increase Autism Risk in ChildrenApril 04, 2025
University of Manchester invites applications for MA Social AnthropologyApril 03, 2025
Ahead of World Health Day, Sova Health Launches Advanced Microbiome Tests & Evidence-Based Precision Supplements April 03, 2025
Half of women cannot make decisions about their reproductive health and bodily autonomyApril 03, 2025
UGRO CAPITAL LIMITED PUBLIC ISSUE OF SECURED, RATED, LISTED, REDEEMABLE, NON-CONVERTIBLE DEBENTURES (SECURED NCDS) OPENS TODAY EFFECTIVE ANNUALIZED YIELD UP TO 11.01% PER ANNUM* April 03, 2025
SF Airlines Entrusts Çelebi India with Freighter Handling at Kempegowda International Airport, BengaluruApril 03, 2025
Is This the Future of Physiotherapy? Inside Stance Health’s $1M ExpansionApril 03, 2025
The Daily Shower Debate: Are You Washing Away Your Skin’s Health?April 03, 2025
The Digital Sleep Thief: How Night-time Screen Addiction is Robbing You of Bed-time RestApril 02, 2025
KKR Launches ‘Knight Bite’ – A Digital Series That Serves Up Food, Fun, and Cricket!April 02, 2025
Crompton rolls out its all new range of Aura, Avancer & Jedi Air Coolers for an effortless summer cooling experienceApril 02, 2025
CARE Hospitals, Hi-Tech City Strengthens Orthopaedics Department with Renowned SurgeonsApril 02, 2025
World Autism Awareness Day: Breaking the Chains of Stigma in IndiaApril 02, 2025
From Scroll to Squint: How Reels Are Reshaping Your VisionApril 02, 2025
Moscow Center for Diagnostics and Telemedicine Receives License for Radiology Residency ProgramApril 02, 2025